Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments

Bristol-Myers Squibb1 site in 1 country55 target enrollmentNovember 25, 2024

ConditionsNon-small Cell Lung Cancer (NSCLC)

InterventionsApproved Non-small Cell Lung Cancer (NSCLC) therapies

Overview

Phase: Not Applicable
Intervention: Approved Non-small Cell Lung Cancer (NSCLC) therapies
Conditions: Non-small Cell Lung Cancer (NSCLC)
Sponsor: Bristol-Myers Squibb
Enrollment: 55
Locations: 1
Primary Endpoint: Responses to qualitative interview questions
Status: Recruiting
Last Updated: 4 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting

Registry

clinicaltrials.gov

Start Date

November 25, 2024

End Date

June 30, 2026

Last Updated

4 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Bristol-Myers Squibb

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Aged ≥18 years at the time of enrollment in the study
•Resident of the US, Germany, or Japan
•Able to read, speak, and understand English, German or Japanese
•Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)
•Resident of the US, Germany, or Japan
•Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology
•Treated at least three new patients with resectable NSCLC in the past year

Exclusion Criteria

•Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
•Being diagnosed with another malignancy alongside NSCLC
•Not willing to be audio-recorded during the interview
•Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
•Not willing to be audio-recorded during the interview

Arms & Interventions

Patients with a diagnosis of resectable non-small cell lung cancer (NSCLC)

Intervention: Approved Non-small Cell Lung Cancer (NSCLC) therapies

Physicians currently treating resectable non-small cell lung cancer (NSCLC) patients

Intervention: Approved Non-small Cell Lung Cancer (NSCLC) therapies

Outcomes

Primary Outcomes

Responses to qualitative interview questions

Time Frame: Day 1

Interview questions designed to gather insights into diagnosis, symptoms, current treatments, perspectives on treatment features and test for mock preferences tasks. The interview will take 15 minutes to complete.

Patient clinical characteristics

Time Frame: Day 1

Patient sociodemographic

Time Frame: Day 1